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The luteinizing hormone (LH) receptor (LHR) is a hep-
tahelical receptor present primarily in the ovaries of fe-
males and the testes of males. This same receptor can
bind with high affinity either pituitary LH or the nearly
identical placental hormone human chorionic gonado-
tropin (hCG). In both males and females, the levels of
LH remain quite low during childhood years, until pu-
berty, at which time the hypothalamic-pituitary-gonadal
axis matures. After puberty, the functions of LH are
critical to normal reproductive function. In postpubertal
males, LH stimulates testosterone synthesis in the Leydig
cells of the testes, which, in turn, is necessary for both
formation of male secondary sexual characteristics and
spermatogenesis. In nonpregnant postpubertal females,
LH plays several roles. During the follicular phase of
the ovarian cycle, LH stimulates theca cells to synthesize
androgens, which are then aromatized into estradiol in
granulosa cells under the influence of follicle-stimulating
hormone (FSH). The midcycle surge of LH induces fol-
licular maturation and ovulation. Subsequently, during
the luteal phase, LH induces the formation of the corpus
luteum and stimulates progesterone synthesis. In the
pregnant female, placental hCG binds to the LHR on
ovarian luteal cells and causes the corpus luteum, which
otherwise undergoes atresia, to be maintained and to
continue steroid synthesis, which is necessary for the
continuation of pregnancy. During pregnancy, if the fe-
tus is male, placental hCG also stimulates fetal testicular
Leydig cells to produce testosterone, which, in turn, me-
diates the differentiation of the external genitalia and
induces the descent of the testes (see Roberts et al. 1999
[in this issue]).
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Clearly, the LHR plays a critical role in reproductive
physiology in both males and females. The importance
of the LHR signal-transduction pathway in normal re-
productive functioning has been further underscored by
the discovery, in recent years, of naturally occurring mu-
tations of the human LHR gene, hLHR.
Structure and Signaling Properties of the LHR
The hLHR gene is composed of 11 exons, and the
gene has been mapped to 2p21 (Rousseau-Merck et al.
1990; Segaloff and Ascoli 1993; Latronico et al. 1997).
The final, 11th exon of the gene encodes the entire car-
boxyl-terminal half of the receptor, including all seven
transmembrane helices, the three interconnecting extra-
cellular loops, the three interconnecting intracellular
loops, and the cytoplasmic tail. This carboxyl half of
the receptor shares homology with other members of the
superfamily of rhodopsin-like G protein–coupled recep-
tors. The first 10 exons of the hLHR gene encode a large
amino-terminal extracellular domain that contains a
number of leucine-rich repeat motifs likely to be involved
in protein-protein interactions. It has been shown that
the extracellular domain of the LHR, when expressed
in isolation in transfected cells, binds hCGwith the same
high affinity as does the full-length receptor. Therefore,
although low-affinity interactions between the carboxyl
half of the receptor and the hormone may also occur,
clearly the high-affinity binding of the hormone is me-
diated by the extracellular N-terminal domain of the
receptor.
Ultimately, the binding of LH or hCG to the LHR
causes it to be stabilized in an active conformation that
can interact with and activate the appropriate hetero-
trimeric G proteins. The LHR has been shown to stim-
ulate phosphatidylinositol phosphate (PIP) production
in cultured cells, but the physiological significance of this
signaling pathway is debatable, since PIP accumulates
only when both the receptor and the hormone are pre-
sent at extremely high levels. In contrast, there is little
or no dispute that the primary pathway activated by
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Table 1
Clinical Manifestations of Activating and Inactivating Mutations of the hLHR Gene in 46,XY and 46,XX Individuals
hLHR Mutation 46,XY Individuals 46,XX Individuals
Activating Familial or sporadic pseudoprecocious puberty Asymptomatic
Inactivating:
Severe defect Leydig-cell hypoplasia with complete female external genitalia Menstrual disorders, cystic ovaries, and infertility
Mild defect Micropenis and/or hypospadias Not described
hormone occupancy of the LHR is the Gs/adenylyl cy-
clase/cAMP pathway.
Naturally occurring mutations in G protein–coupled
receptor genes can cause human disease by producing
either gain- or loss-of-receptor function. The elucidation
of the cDNA sequence and genomic organization of the
hLHR have made it possible to identify hLHRmutations
that can be directly linked to specific reproductive dis-
orders (see table 1).
Activating Mutations of the hLHR: Identification and
Clinical Presentation
Several dominant gain-of-function mutations in the
hLHR gene have been found in males with sporadic or
familial male-limited gonadotropin-independent pseu-
doprecocious puberty, also known as “testotoxicosis”
(Kremer et al. 1993; Shenker et al. 1993; Yano et al.
1994, 1996; Kawate et al. 1995; Kosugi et al. 1995;
Kraaij et al. 1995; Latronico et al. 1995, 1998; Laue et
al. 1995a; Evans et al. 1996; Rosenthal et al. 1996;
Gromoll et al. 1998). In the presence of a heterozygous
activating mutation, boys with this condition display
elevated levels of testosterone, although their GnRH and
LH levels remain prepubertal (Shenker et al. 1993), sug-
gesting that the LHR-signaling pathway in their Leydig
cells is activated, even in the absence of hormonal stim-
ulation. This disorder, which usually is present by age
1–4 years, is characterized by signs of puberty, rapid
virilization, and linear-growth acceleration (Shenker et
al. 1993; Kraaij et al. 1995; Latronico et al. 1995, 1998;
Laue et al. 1995a; Gromoll et al. 1998). All gain-of-
function missense mutations described to date have been
found in the carboxyl half of the hLHR, with most of
them clustering within the sixth transmembrane helix
and third intracellular loop. Although this may indicate
a prevalence of gain-of-function mutations in this region
of the hLHR gene, it must be cautioned that in many
of the earlier studies only a small portion of the 11th
exon encompassing the third intracellular loop and sixth
transmembrane helix had been examined for potential
mutations. Indeed, activating mutations have also been
described in helices I–V (fig. 1). Cells transfected with
the cDNAs for the mutant hLHRs exhibit markedly in-
creased cAMP production in the absence of agonist, sug-
gesting that autonomous Leydig-cell activity in this form
of male precocious puberty results from constitutive ac-
tivation of the hLHR (Shenker et al. 1993). Interestingly,
basal levels of cAMP in cells that express the constitu-
tively active hLHRs are not as great as the levels attained
in response to a saturating concentration of hormone.
Therefore, in most cases, the constitutively active mu-
tants still respond further to hormonal stimulation.
However, of the 13 activating mutations of the hLHR
described thus far, 3 (Leu457Arg, Ile542Leu, and
Cys581Arg) cause elevated basal cAMP production but
prevent the mutant receptors from responding to further
stimulation by hCG (Laue et al. 1995a; Latronico et al.
1998).
46,XX female mothers or sisters of boys with male-
limited pseudoprecocious puberty show normal ovarian
function, despite carrying constitutively activating mu-
tations of the hLHR gene in heterozygous form. Rosen-
thal et al. (1996) have evaluated the pituitary-gonadal
axis of a mother of two sons who had familial male-
limited precocious puberty due to the most common
constitutively activating mutation (Asp578Gly) of the
hLHR gene in the United States. The mother’s dynamics
of LH, FSH, and androgen secretion were normal in the
basal state and after acute or chronic GnRH agonist or
dexamethasone administration. Thus, activating hLHR
mutations do not appear to cause functional ovarian
hyperandrogenism in mature women. This may be be-
cause ovarian theca cells are less efficient than testicular
Leydig cells in steroid biosynthesis at the level of 17,20-
lyase, which is the rate-limiting step in androgen for-
mation (Ehrman et al. 1995).
Molecular and Cellular Mechanisms Underlying
Activating hLHR Mutations
As with other G protein–coupled receptors, activat-
ing mutations of the hLHR are thought to stabilize the
receptor in an activated state. The current paradigm
for G protein–coupled receptor activation is based on
the revised ternary complex model (Samama et al.
1993; Bond et al. 1995). In this model, it is presumed
that the unoccupied receptor exists in an equilibrium
between inactive (R) and active (R*) conformations.
The preferential binding of agonist to R* causes G-
protein activation by shifting the equilibrium toward
the active H-R* state. Mutations that cause ligand-
Figure 1 Gain-of-function mutations of the hLHR gene. The schematic representation of the hLHR indicates positions of constitutively activating mutations of the hLHR gene that cause sporadic
or familial male-limited pseudoprecocious puberty.
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independent activation of a G protein–coupled receptor
are thought to do so by also shifting the equilibrium
toward the R* state. Whether the R* state of a con-
stitutively active mutant is structurally equivalent to
the R* state of the agonist-occupied receptor is a ques-
tion undergoing active investigation. Some studies have
suggested that the R* state of a constitutively active
mutant may be intermediate between R and the R*
state of the agonist-occupied receptor and that there
may be many R* states (Hjorth et al. 1998).
Studies with other G protein–coupled receptors sup-
port a general model, reviewed by Gether and Kobilka
(1998), according to which receptor activation involves
the increased movement of one or more helices, which
opens the cytoplasmic cleft to expose specific sites for
G-protein interaction and activation. In particular, the
movement of helices III and VI relative to each other has
been proposed to be the activation switch for G pro-
tein–coupled receptors (Baranski et al. 1999; Sheikh et
al. 1999). Consistent with this model, studies of some
activating mutations of the hLHR gene have suggested
that the mutations introduce alterations in interhelical
interactions (Kjelsberg et al. 1992; Kosugi et al. 1996,
1997, 1998). Studies of other G protein–coupled recep-
tors suggest that, in the activated state, regions of the
cytoplasmic loops in close juxtaposition to the plasma
membrane form the G protein–binding pocket. Recent
studies suggest that, at least for the hLHR, regions
within the transmembrane helices themselves—in par-
ticular, helix VI—may also be directly involved in Gs
activation (Abell and Segaloff 1997; Abell et al. 1998).
Inactivating Mutations of the hLHR: Identification
and Clinical Presentation
Loss-of-function mutations of the hLHR gene result
in testicular resistance to LH, leading to Leydig-cell hy-
poplasia (Kremer et al. 1995; Latronico et al. 1996).
During the first trimester of normal male embryogenesis,
hCG induces the differentiation of testicular mesenchy-
mal cells into Leydig cells and stimulates androgen pro-
duction by these cells, which are responsible for virili-
zation of the undifferentiated external genitalia. During
the second and third trimesters, LH stimulates the Leydig
cells to produce testosterone, which is responsible for
penile growth. Leydig-cell hypoplasia is a rare form of
autosomal recessive male pseudohermaphroditism, char-
acterized by failure of fetal testicular Leydig-cell differ-
entiation (Bertezene et al. 1976; Schwartz et al. 1981;
Saldanha et al. 1987). Affected 46,XY males are im-
paired in this process and may display female external
genitalia or a micropenis, sometimes accompanied by
hypospadias (Bertezene et al. 1976; Schwartz et al. 1981;
Kremer et al. 1995; Latronico et al. 1996). Affected in-
dividuals with complete female external genitalia usually
have a female gender and, therefore, seek medical at-
tention only when their breast development and men-
strual periods fail to occur at the expected time of pu-
berty. Mu¨llerian derivatives are absent, but an
epididymis and vas deferens may be identified histolog-
ically. Testes are inguinal or intraabdominal and reach
near-normal size after puberty, with relatively preserved
seminiferous tubules but no differentiated Leydig cells.
Levels of LH are elevated, and levels of testosterone and
its precursors are low and fail to increase with hCG
administration.
Eleven distinct mutations of the hLHR gene have been
described among nine unrelated kindreds with Leydig-
cell hypoplasia (see fig. 2) (Kremer et al. 1995; Laue et
al. 1995b, 1996; Latronico et al. 1996, 1997; Misrahi
et al. 1997; Martens et al. 1998; Stavrou et al. 1998;
Wu et al. 1998). Two partial deletions, one insertion,
and seven single-base-pair substitutions impair or elim-
inate hormone-stimulated signal transduction when ex-
pressed in cultured cells (Laue et al. 1995b, 1996; La-
tronico et al. 1997; Misrahi et al. 1997; Martens et al.
1998; Stavrou et al. 1998; Wu et al. 1998). Although
Leydig-cell hypoplasia generally results from a homo-
zygous inactivating hLHR gene mutation, it can also
result from compound heterozygous loss-of-function
mutations (Laue et al. 1996; Wu et al. 1998).
The first of the severe hLHR mutations that cause
male pseudohermaphroditism associated with Leydig-
cell hypoplasia was reported by Kremer et al. (1995),
who identified a homozygous Ala593Pro mutation in
the sixth transmembrane domain of the hLHR in two
46,XY siblings with female external genitalia. Cells ex-
pressing the recombinant form of this hLHR mutant do
not induce cAMP production in response to hCG (Kre-
mer et al. 1995). A different homozygous nonsense mu-
tation (Arg554Stop) was subsequently found in the third
intracellular loop of the hLHR in three male pseudoh-
ermaphrodite siblings with female phenotypes and Ley-
dig-cell hypoplasia and also in a 46,XX sister with sec-
ondary amenorrhea (Latronico et al. 1996). Although it
is not known whether the mutant mRNA is stably ex-
pressed or degraded, if it were expressed, the premature
stop codon would eliminate a large portion of the re-
ceptor (Latronico et al. 1996). Recently, another severe
hLHR inactivating mutation was identified as a homo-
zygous microdeletion of Leu608 and Val609 in the sev-
enth transmembrane region of the hLHR. This mutation
was identified in two related patients, a male pseudo-
hermaphrodite with female external genitalia and his
sister with oligoamenorrhea and infertility (Latronico et
al. 1997). Cells expressing this hLHR mutant are do not
respond to hCG with increased cAMP production (La-
tronico et al. 1997).
Milder inactivating mutations of the hLHR have been
described that permit partial LH function in males
Figure 2 Loss-of-function mutations of the hLHR gene. The schematic representation of the hLHR indicates positions of hLHR mutations in males and females with LH/hCG resistance. The
blackened area indicates the extracellular region that is deleted on deletion of exon 8. The triangle indicates the position of an 11-amino-acid insertion.
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(Latronico et al. 1996; Laue et al. 1996; Misrahi et al.
1997; Martens et al. 1998). A homozygous substitution,
Ser616Tyr, in the seventh transmembrane helix of the
hLHR gene was first reported in a boy from Puerto Rico
who had micropenis, bilaterally descended testes, and
no response to exogenous hCG (Latronico et al. 1996).
The same mutation was carried by the asymptomatic
parents of the patient, who were heterozygous for this
amino acid substitution, suggesting that one defective
hLHR allele causes no abnormality in either sex (La-
tronico et al. 1996). A more recent report described a
compound-heterozygous mutation of the hLHR gene in
another Puerto Rican boy with Leydig-cell hypoplasia,
who had micropenis associated with severe perineoscro-
tal hypospadias and cryptorchidism (Laue et al. 1996).
This individual carries both a deletion of the entire exon
8 in one hLHR allele and two different missense mu-
tations in the other allele. Martens et al. (1998) have
reported the homozygous mutation Ile625Lys, located
at the border between the seventh transmembrane helix
and the cytoplasmic tail of the hLHR, in three other
brothers with micropenis. All mutations described above
resulted in impaired hCG-stimulated cAMP production
in cells expressing the mutant receptors, suggesting a
clear correlation between the severity of the clinical phe-
notype of patients and overall receptor signal capac-
ity, which reflects both cell-surface expression levels and
coupling efficiency (Laue et al. 1996; Martens et al.
1998).
In normal women, LH stimulates the theca cells to
produce androgen precursors for aromatization to es-
tradiol by granulosa cells during the follicular phase of
the menstrual cycle. Subsequently, during its midcycle
surge, LH promotes follicular maturation and ovulation,
and, during the luteal phase, LH induces the formation
of the corpus luteum and stimulates progesterone secre-
tion. Thus, abnormalities in the LH receptor would be
expected to result in partial ovarian failure, character-
ized by defective folliculogenesis, anovulation, and the
absence of progesterone secretion during the second
phase of the menstrual cycle. Such abnormalities would
be predicted to cause delayed or incomplete feminization
at puberty, amenorrhea, and infertility.
To date, only four genetic females have been described
with hLHR inactivating mutations (Latronico et al.
1996, 1997; Toledo et al. 1996; Stavrou et al. 1998).
These women, sisters of 46,XY individuals with Leydig-
cell hypoplasia, carry homozygous or compound-het-
erozygous inactivating mutations of the hLHR gene.
Women with ovarian resistance to LH exhibit normal
female external genitalia and experience normal breast
development and pubic hair growth at puberty but are
amenorrheic or have menstrual irregularities and, as ex-
pected, are infertile (Toledo et al. 1996; Arnhold et al.
1997). Plasma LH levels in these woman are elevated,
with a high LH:FSH ratio, and their estradiol concen-
trations are within the normal late-follicular-phase
range, although their progesterone concentrations do
not reach postovulatory levels (Arnhold et al. 1997,
1999). In some cases, the uterus is hypoplastic and the
ovaries are enlarged and contain several cysts. Ovarian
biopsy reveals antral follicles with proliferative activity
of granulosa and theca cells but no corpora lutea or
albicans (Arnhold et al. 1997).
The normal pubertal feminization in women with in-
activating mutations of the hLHR suggests that LH is
not essential for female pubertal development. Instead,
LH appears to be essential to stimulate the ovaries to
secrete normal preovulatory estrogen levels, to induce
ovulation, to cause corpus luteum formation, and to
sustain the function of the corpus luteum through the
luteal phase of the cycle.
Molecular and Cellular Mechanisms Underlying
Inactivating hLHR Mutations
Several distinct alterations in intracellular events may
account for the loss of LH/hCG responsiveness in go-
nadal cells that carry loss-of-function hLHR mutations.
In contrast to gain-of-function mutations, which cause
an increase in the constitutive basal activity of the hLHR,
a loss-of-function mutation may or may not be due to
a decrease in the intrinsic signaling properties of the
hLHR. Thus, cell-surface hLHRs may be unresponsive
to LH/hCG as a result of decreased hormone-binding
affinity or impaired ability of the receptor to activate
Gs. Furthermore, decreased gonadal-cell responsiveness
may be due to a decrease in the number of cell-surface
hLHRs expressed. This situation may arise if a mutation
alters the total amount of receptor expressed, by de-
creasing either mRNA or receptor-protein levels. Con-
comitantly or independently, there may be a reduction
in the percentage of receptor that is processed properly
and targeted to the plasma membrane. This can occur
if a mutation causes the hLHR to be improperly folded
and retained in the endoplasmic reticulum (Rozell et
al. 1995; Latronico et al. 1997). These events are not
mutually exclusive. Thus, one loss-of-function hLHR
mutation (DL608,V609), appears to reduce target-cell
responsiveness, by a combination of mechanisms (La-
tronico et al. 1997). Cells expressing this mutant recep-
tor exhibit only 10% of the cell-surface receptors as cells
expressing the wild-type receptor, both because of a de-
crease in the total amount of hLHR expressed and be-
cause of an increased intracellular retention of the hLHR
mutant. Moreover, those receptors that reach the cell
surface bind hCG with high affinity but are unable to
mediate increased cAMP production.
Because the basal as well as hormone-stimulated levels
of cAMP production are dependent on the number of
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cell-surface receptors, the signaling properties of cells
expressing a hLHR mutant can be assessed only in com-
parison with those of cells that express comparable levels
of wild-type hLHR. However, in many reports that iden-
tify loss-of-function mutations of the hLHR gene, the
expression of the mutant receptor is much lower than
that of the wild-type receptor, so it is not valid to con-
clude that these mutants are impaired in signaling per
se. Nonetheless, the decreased levels of cell-surface mu-
tant hLHR could be sufficient to account for the de-
creased gonadal responsiveness to LH/hCG.
Perspective
The identification and characterization of naturally
occurring mutations of the hLHR gene have consider-
ably advanced our understanding of the actions of this
receptor in reproductive physiology. Not surprisingly,
however, these studies prompt additional questions and
the need for further investigation.
One intriguing outcome of these studies is the obser-
vation that precocious puberty is observed only in males
carrying activating mutations of the hLHR gene and not
in females. It has been suggested that females require
the activation of both the hLHR and human follitropin
receptor (hSHR) or predominantly the hFSHR for the
induction of puberty—and that, thus, the constitutive
activation solely of the hLHR would be insufficient to
induce this process (Kremer et al. 1993; Rosenthal et al.
1996). (Although both hLHR and hFSHR activate Gs,
their cellular and temporal expression in the ovary dif-
fers, and, thus, activation of one or the other receptor
would have different physiological effects.) It is relevant
that hCG-secreting tumors promote precocious puberty
in boys but not in girls, supporting the idea that ovarian
function in humans is dependent on activation of both
hLHR and hFSHR. Consistent with this is the obser-
vation that both males and females exhibiting McCune-
Albright syndrome (MAS) undergo precocious puberty.
This syndrome arises from activating mutations of the
GNAS1 gene, which encodes the a-subunit of the tri-
meric Gs protein. Individuals withMAS (who aremosaic
for this defect, since these mutations are usually lethal
in utero) thus have a postreceptor activation that in-
cludes both the hLHR and the hFSHR pathways. Inter-
estingly, there may be a species difference with respect
to whether activation of the LHR and/or of the FSHR
causes puberty. Thus, transgenic female mice, but not
male mice, harboring a transgene that causes overex-
pression of LH exhibit precocious puberty (Risma et al.
1997). Therefore, caution must be used in extrapolating
from one species to another, with regard to the role that
the LHR and the FSHR play in the induction of puberty.
Within the superfamily of rhodopsin-like G pro-
tein–coupled receptors, the LHR is most closely related
to the FSHR and the thyrotropin receptor (TSHR), all
of which have large hormone-binding extracellular do-
mains and interact with Gs. As discussed herein, males
with gonadotropin-independent precocious puberty
have been a valuable resource for the identification of
activating mutations of the hLHR gene. Similarly, the
screening of individuals with thyroid adenomas has led
to the identification of many activating mutations of
the human TSHR gene, hTSHR (Epstein 1997). Be-
cause, in humans, activation of the hFSHR alone would
not be expected to cause precocious puberty in males,
individuals with gonadotropin-independent precocious
puberty would not be a suitable choice for identifica-
tion of activating mutations of the hFSHR gene. It had
been hypothesized that constitutive activation of the
hFSHR gene may underlie some granulosa-cell tumors;
however, screening of these thus far has not yielded any
activating mutations of the hFSHR gene. Only one pu-
tative constitutively activating mutation of the hFSHR
gene has been reported (Gromoll et al. 1996). This
mutation was originally identified in a hypophysectom-
ized male who exhibited normal testes volume and fer-
tility after testosterone treatment. In the initial report,
the observed increase in basal cAMP in cells transfected
with hFSHR(D567G) was quite low. A subsequent
study by a different group was unable to demonstrate
any elevation of basal cAMP in cells transfected with
hFSHR(D576G) (Kudo et al. 1996). Therefore, the
D576G substitution may represent a nonfunctional
polymorphic mutation in the hFSHR—and a different,
as yet unidentified, mutation may cause the phenotype
of the patient in the original study. Alternatively, the
D576G mutation may cause only a minor constitutive
activation of the hFSHR, which might make it difficult
to observe in a reproducible manner. In either case, the
D576G mutation in the hFSHR is in marked contrast
to both the comparable D564G mutation in the hLHR
and the D633 substitution in the hTSHR, which cause
significant constitutive activation of these receptors.
Furthermore, two other mutations, one in the third
intracellular loop and one in helix VI, which are known
to induce constitutive activation of the hLHR, have
been shown to have no effect on the hFSHR (Kudo et
al. 1996). The hFSHR is not entirely refractory to mu-
tation-induced constitutive activation, because a mu-
tation of a highly conserved leucine in transmembrane
helix III causes constitutive activation (Y. X. Tao, X.
Liu, K. Nakamura, and D. L. Segaloff, unpublished
data). Thus, although the hFSHR can be made consti-
tutively active, it differs significantly from the hLHR,
in terms of the role that residues in the sixth trans-
membrane helix and in the third intracellular loop play
in maintenance of the inactive state.
As discussed earlier, the clustering of many of the ac-
tivating mutations of the hLHR in helix VI may have
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arisen in part because of the sequencing, in earlier stud-
ies, of only that small portion of the gene. Nonetheless,
the large preponderance of activating mutations of the
hLHR in helix VI is certainly consistent with the pro-
posed role of the movement of helix VI during the ac-
tivation of other G protein–coupled receptors (Baranski
et al. 1999; Sheikh et al. 1999) and with studies sug-
gesting a possible interaction of hLHR helix VI with Gs
(Abell and Segaloff 1997; Abell et al. 1998). On the
other hand, the ability of mutations in many other hLHR
helices to induce constitutive activation also underscores
the complexity of the activation of G protein–coupled
receptor activation and reflects the key role that changes
in interhelical interactions play in this activation process.
The inactivating mutations of the hLHR are even
more widespread throughout the gene, affecting regions
not only in the carboxyl half of the receptor but also in
the extracellular domain. This reflects the observation
that most of the inactivating mutations of the hLHR
result in decreased target-cell responsiveness, because of
decreased expression of the mutants on the cell surface.
From these studies, as well as mutagenesis studies on
the rat LHR, it is clear that the LHR is very susceptible
to mutations that cause misfolding and intracellular re-
tention of the receptor in the endoplasmic reticulum
(Rozell et al. 1995). Furthermore, mutations in any por-
tion of the receptor may result in intracellular retention,
and no pattern is apparent. These observations under-
score the necessity of learning more about the folding
and processing of the hLHR, if there ever is to be a
strategy for “rescuing” otherwise functional but intra-
cellularly retained mutants. The actual signaling prop-
erties of most inactivating hLHR mutants remain un-
certain because of their poor expression and will require
thorough study to determine which mutants would be
functional if they could be induced to the cell surface.
Such data would also provide further insight into the
mechanism of activation of the hLHR.
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